This article is more than 5 years old. Information may no longer be current.

Akorn receives FDA approval for ofloxacin ophthalmic solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFFALO GROVE, Ill. — Akorn's abbreviated new drug application for ofloxacin ophthalmic solution 0.3% has been approved by the U.S. Food and Drug Administration, the company announced in a press release.

Ofloxacin is an anti-infective agent indicated for treating infections caused by bacterial conjunctivitis and corneal ulcers, the release said.

Akorn expects to launch ofloxacin in the third quarter of 2008.